Pharmaceutical Technology

JULY 7, 2023

The EMA has granted Novavax’s Covid-19 vaccine a full marketing authorisation, based on Phase III trial data.

Vaccination 130

Vaccination Vaccine Marketing Trials 130

Pharmaceutical Technology

OCTOBER 28, 2022

On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. This is in addition to its long-available pneumococcal polysaccharide vaccine PPSV23.

Vaccination 162

Vaccination Vaccine Marketing Bacteria 162

Pharmaceutical Technology

JULY 25, 2022

The European Commission (EC) has extended Bavarian Nordic ’s smallpox vaccine Imvanex (MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic) marketing authorisation to offer protection from monkeypox. A non-replicating smallpox vaccine, Imvanex was developed in partnership with the US Government.

Vaccination 130

Vaccination Vaccine Marketing Medicine 130

Bio Pharma Dive

OCTOBER 21, 2022

The company is considering charging as much as between $110 and $130 per dose — roughly four times the vaccine’s current price — once sales transition to the private market.

Vaccination 347

Vaccination Vaccine Sales Marketing 347

Bio Pharma Dive

JULY 24, 2023

The shot failed to meet a key goal of Bavarian Nordic’s Phase 3 study, a finding that separates it from marketed vaccines developed by Pfizer and GSK.

Vaccination 246

Vaccination Vaccine Marketing Development 246

pharmaphorum

MAY 12, 2024

Moderna’s respiratory syncytial virus (RSV) vaccine has suffered a delay in the US as it chases GSK and Pfizer in the market.

Vaccination 111

Vaccination Vaccine Marketing 111

Pharmaceutical Technology

SEPTEMBER 21, 2023

The collaboration will use Evaxion’s EDEN platform to bring an AI-designed gonorrhea mRNA vaccine to the market.

Vaccination 246

Vaccination Vaccine Development Marketing 246

BioSpace

NOVEMBER 30, 2023

CEO Emma Walmsley projects that the British biopharma’s Arexvy sales will exceed £1 billion in its first year on the market, leaving Pfizer’s Abrysvo respiratory syncytial virus vaccine far behind in the race.

Vaccination 118

Vaccination Vaccine Marketing Sales 118

Pharmaceutical Technology

MARCH 28, 2023

Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. The company saw major successes with its Covid-19 vaccine, developed in collaboration with Pfizer. In response to the lower vaccine sales forecasts, BioNTech shares opened at 3.9%

Vaccination 276

Vaccination Vaccine Development Clinical Trials 276

Pharmaceutical Technology

FEBRUARY 7, 2023

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Takeda ’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]). The vaccine candidate has been approved for active immunisation against the infection in people from four years of age.

Vaccination 264

Vaccination Vaccine Genetics Trials 264

BioSpace

MAY 8, 2024

AstraZeneca announced that it will voluntarily pull Vaxzevria from the global market amid a sharp decline in demand and following the company’s recent admission that its vaccine is linked with a rare side effect.

Vaccination 109

Vaccination Vaccine Marketing 109

World of DTC Marketing

AUGUST 10, 2022

CPG marketers are trying to maintain market share amid price increases and smaller product sizes, leading to a more significant jump in consumerism. But, in pharma marketing, the changes affect every product category. However, DTC marketing is different, much different. So what’s the opportunity for DTC marketers?

Marketing 252

Marketing Production Drugs Doctors 252

Pharmaceutical Technology

APRIL 13, 2023

The expanded licence will include the development of vaccines and therapeutic proteins beyond Covid-19 for human and animal health markets in Africa. During the Covid-19 pandemic, vaccination rates of many countries in Africa were significantly trailing the rest of the world.

Production 279

Production Vaccination Vaccine Protein 279

Pharmaceutical Technology

APRIL 11, 2023

The US government is reportedly investing more than $5bn in a programme to accelerate the development of new Covid-19 vaccines and treatments. Health experts have lent their support to the new programme as the existing vaccines may not be as effective against future virus threats.

Vaccination 264

Vaccination Vaccine Development Antibody 264

Pharmaceutical Technology

DECEMBER 20, 2022

The top 20 global biopharmaceutical companies exhibited a downward trend in aggregate market capitalisation by 9.1% This downturn in market cap was attributed to a decline in the demand for Covid-19 vaccines and therapies. Bayer recorded a negative market capitalization growth of 22.3% trillion in Q2 2022 to $3.14

Marketing 130

Marketing Vaccination Vaccine Sales 130

Fierce Pharma

JANUARY 10, 2023

JPM23: Novavax hopes end of COVID emergency—and open vaccine market—will help it grow market share. aarmstrong. Tue, 01/10/2023 - 10:24.

Marketing 112

Marketing Vaccination Vaccine 112

Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccination 245

Vaccination Vaccine Development RNA 245

Pharmaceutical Technology

MAY 23, 2023

Croda Pharma has entered a strategic collaboration deal with Botanical Solution Inc (BSI) to expedite the production of sustainable pharmaceutical-grade vaccine adjuvant QS-21. Croda Pharma and BSI will share their knowledge to bring QS-21 to market from quillaja Saponaria plant cell culture, which is made from the soap bark tree. “The

Production 240

Production Vaccination Vaccine Life Science 240

Pharmaceutical Technology

OCTOBER 19, 2023

Novavax has received full marketing authorisation from the UK’s MHRA for its prototype Covid-19 vaccine Nuvaxovid (NVX-CoV2373).

Marketing 130

Marketing Vaccination Vaccine 130

pharmaphorum

JUNE 29, 2023

Sanofi sets out plan to lead the RSV vaccine market Phil.Taylor Thu, 29/06/2023 - 10:31 Bookmark this

Vaccination 104

Vaccination Vaccine Marketing 104

Fierce Pharma

AUGUST 15, 2023

As COVID-19 vaccine makers gear up to launch updated shots in the private market, can the new vaccines keep up with the virus? zbecker Tue, 08/15/2023 - 09:48

Vaccination 94

Vaccination Vaccine Marketing 94

Fierce Pharma

MAY 2, 2024

With Moderna’s COVID-19 sales on the backfoot following the switch to an endemic vaccine market, the Massachusetts-based biopharma is busy laying the groundwork for its next potential mRNA shot in | Moderna currently expects initial approvals of its RSV vaccine to start rolling in during the first half of 2024, the company said Thursday.

Vaccination 104

Vaccination Vaccine Sales Marketing 104

Fierce Pharma

MAY 6, 2024

As BioNTech continues to endure a sharp decline in COVID-19 vaccine sales, the German mRNA specialist is looking ahead to the next leg of its commercial journey. With plans to have at least 10 potentially registrational trials underway by the end of 2024, BioNTech is plotting the first wave of its market debut in oncology from 2026 onward.

Sales 125

Sales Vaccination Vaccine Trials 125

Pharmaceutical Technology

MAY 26, 2023

The immuno-oncology market continues to evolve as treatments establish their presence across different types of cancer, having seen approvals in multiple indications in the past decade. GlobalData separates immuno-oncology treatments into six broad classes, which include bispecific antibodies, cancer vaccines, and cell therapies.

Marketing 264

Marketing Vaccination Vaccine Development 264

BioSpace

DECEMBER 11, 2023

With the acquisition, AstraZeneca will gain access to Icosavax’s investigational combination vaccine IVX-A12, which is being developed for respiratory syncytial virus and human metapneumovirus in older adults.

Vaccination 108

Vaccination Vaccine Marketing Development 108

Bio Pharma Dive

NOVEMBER 1, 2023

Sales of GSK’s new RSV shot Arexvy were more than double what Pfizer reported for its rival product, suggesting substantial demand this fall.

Marketing 156

Marketing Vaccination Vaccine Sales 156

Pharmaceutical Technology

JULY 6, 2022

The European Commission (EC) has granted approval for the expanded conditional marketing authorization (CMA) of Novavax’s Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), in the European Union (EU) for adolescents of the age 12 to 17 years. In April this year, the company sought CMA expansion from the EC for the vaccine use in adolescents.

Vaccination 264

Vaccination Vaccine Protein Clinical Trials 264

Fierce Pharma

JANUARY 20, 2023

JPM23: Pfizer, Moderna and more look to combine COVID and flu vaccine markets zbecker Fri, 01/20/2023 - 14:48

Vaccination 128

Vaccination Vaccine Marketing 128

Pharmaceutical Technology

SEPTEMBER 15, 2023

The EMA CHMP has recommended granting marketing authorisation for Moderna’s updated Covid-19 vaccine targetting XBB.1.5 sublineage.

Vaccination 147

Vaccination Vaccine Marketing 147

Fierce Pharma

APRIL 1, 2024

While the market for COVID-19 vaccines has been shrinking lately, an investigation into text messages between Pfizer CEO Albert Bourla and the European Commission’s President Ursula von der Leyen r | The European Public Prosecutor’s Office (EPPO) took over the investigation into COVID vaccine negotiations between the European Commission's president (..)

Vaccination 119

Vaccination Vaccine Marketing 119

Pharmaceutical Technology

DECEMBER 8, 2022

5-adapted bivalent Covid-19 vaccine for usage in children aged six months to four years. The vaccine is indicated for use as a third 3µg dose in the three-dose initial regimen for children of this age group. Earlier this month, the companies sought FDA EUA for the Omicron-adapted vaccine for use in children aged below five years.

Vaccination 246

Vaccination Vaccine Manufacturing Marketing 246

Pharmaceutical Technology

FEBRUARY 8, 2023

The top 20 companies in the global biopharma industry saw 5.4%* aggregate market capitalization from $3.43 The 13 top players experienced significant growth over 2022 despite the decline in demand for COVID-19 vaccines and therapeutics, as well as uncertainty surrounding pricing due to the newly passed Inflation Reduction Act in the US.

Marketing 195

Marketing Sales Vaccination Vaccine 195

Bio Pharma Dive

SEPTEMBER 27, 2023

Despite the company's recent Phase 3 setbacks in RSV and COVID, CEO Paul Chaplin sees a path forward for the Dutch biotech in the travel vaccine market.

Vaccination 156

Vaccination Vaccine Marketing 156

Pharmaceutical Technology

MAY 25, 2023

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. percentage points (96% CI, −0.3

Vaccination 195

Vaccination Vaccine Immune Response Bacteria 195

Fierce Pharma

MAY 1, 2024

Even with the threat of a potential new competitor in the respiratory syncytial virus (RSV) vaccine race on the horizon, GSK and its leading Arexvy shot aren’t sweating. | The company's respiratory syncytial virus vaccine Arexvy takes some two-thirds of the RSV market share, GSK reported. adults to its reach.

Marketing 94

Marketing Vaccination Vaccine 94

World of DTC Marketing

NOVEMBER 10, 2020

You need to ask yourself why in the hell Pfizer’s CEO would say that their vaccine is 90% effective when there is a lot more testing and review of data needed. The answer lies in looking at Pfizer’s stock price which shot up on the news as well as the false optimism of the stock market. The media has not been helpful.

Vaccination 286

Vaccination Vaccine Marketing Drugs 286

Pharmaceutical Technology

NOVEMBER 25, 2022

XtalPi has entered a strategic partnership with CK Life Sciences for artificial intelligence (AI)-driven tumour vaccine research and development (R&D). Under the collaboration, the companies will utilise their capabilities to co-develop a new AI tumour vaccine R&D platform.

Life Science 246

Life Science Vaccination Vaccine Development 246